# Kevin Kinsella

> Kevin Kinsella is a Series A investor at Avalon Ventures backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Avalon Ventures](https://shizune.co/investors/profile/avalon-ventures)
- Location: La Jolla, United States
- Total investments: 7
- Last investment: Nov 2022
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kevin-kinsella-b24945122
- Facebook: https://www.facebook.com/kevin.j.kinsella

Kevin Kinsella is a Series A investor at Avalon Ventures in La Jolla focused on Biotechnology and Medical. Kevin J. Kinsella is based out of La Jolla, California and is the Founder and Managing Director of Avalon Ventures. Kevin previously worked at Solar Turbines International as a director. Kevin J. Kinsella attended the Massachusetts Institute of Technology. Kevin J. Kinsella has been received the 2006 Tony Award.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Health Care | 2 | 29% |
| Real Time | 1 | 14% |
| Life Science | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 2 | 29% |
| Series C | 2 | 29% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jnana Therapeutics | Jnana Therapeutics is a biotechnology company focused on discovering and developing medicines that improve patient lives. Utilizing its RAPID platform, the firm accelerates the identification of therapeutic targets and the creation of small molecule therapies for various diseases. Jnana aims to enhance drug discovery efficiency through advancedchemoproteomics techniques, addressing unmet medical needs. | $107M | Series C | Nov 15, 2022 |  |
| Jnana Therapeutics | Jnana Therapeutics is a biotechnology company focused on discovering and developing medicines that improve patient lives. Utilizing its RAPID platform, the firm accelerates the identification of therapeutic targets and the creation of small molecule therapies for various diseases. Jnana aims to enhance drug discovery efficiency through advancedchemoproteomics techniques, addressing unmet medical needs. | $50M | Series A | Dec 14, 2017 |  |
| Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $20M | Series C | Aug 18, 2016 |  |
| Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $7.4M | Series B | Sep 10, 2014 |  |
| Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $6.8M | Series B | Jan 09, 2014 |  |
| Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $7.7M | Series A | Dec 06, 2012 |  |
| Amira Pharmaceuticals | Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructivepulmonary disease, cardiovascular and fibrotic diseases. | $25M | Series B | Mar 23, 2007 |  |

7 of 7 investments shown.

## Co-investors
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 3 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 2 deals together
- [Torrey Pines Investment](https://shizune.co/investors/profile/torrey-pines-investment) — VC Fund, 2 deals together
- [WuXi Healthcare Ventures](https://shizune.co/investors/profile/wuxi-healthcare-ventures) — VC Fund, 2 deals together
- [AbbVie](https://shizune.co/investors/profile/abbvie) — VC Fund, 1 deal together
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 1 deal together

## About Avalon Ventures

VC Fund · La Jolla, United States

Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.

5 contacts available at Avalon Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Court Turner | Venture Partner | https://shizune.co/investors/profile/court-turner |
| Kevin Kinsella | Founder and Managing Director | https://shizune.co/investors/profile/kevin-kinsella |
| Steve Tomlin | Managing Member | https://shizune.co/investors/profile/stephen-tomlin |
| Brady Bohrmann | Managing Member | https://shizune.co/investors/profile/brady-bohrmann |
| Richard Levandov | Partner | https://shizune.co/investors/profile/richard-levandov |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kevin Kinsella invest in?

Kevin Kinsella invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kevin Kinsella last invest?

The most recent investment recorded for Kevin Kinsella closed in Nov 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co